Chemomab therapeutics regains compliance with nasdaq minimum bid price requirement

Tel aviv, israel, july 26, 2024 (globe newswire) -- chemomab therapeutics ltd. (nasdaq: cmmb) (chemomab) a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it has received a notification letter from the listing qualifications department of the nasdaq stock market (“nasdaq”), informing the company that it has regained compliance with the minimum bid price requirement set forth in nasdaq listing rule 5550(a)(2).
NDAQ Ratings Summary
NDAQ Quant Ranking